CRSP
CRSP clinical trials: CRISPR Therapeutics AG
Every trial on ClinicalTrials.gov where CRISPR Therapeutics AG is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 21
- Trials linked
- 16
- As lead sponsor
- 5
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
CRSP on the catalyst calendar · CRSP registry changes
- Primary completion Jun 2030Sponsor estimatePhase 1/Phase 2NCT07850076A Trial Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of CTX460 in Adults With Emphysema...CRISPR Therapeutics · Alpha-1 Antitrypsin Deficiency (AATD)RecruitingCRSPLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 1, 2028Sponsor estimatePhase 1/Phase 2NCT07758634A Trial Evaluating Safety, Tolerability and Efficacy of CTX340 in Participants With HypertensionCRISPR Therapeutics AG · HypertensionRecruitingCRSPLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 11, 2026ActualPhase 1NCT06492304A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic MalignanciesCRISPR Therapeutics · T Cell LymphomaCompletedCRSPLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 18, 2025ActualPhase 1NCT05795595A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid TumorsCRISPR Therapeutics AG · Clear Cell Renal Cell CarcinomaCompletedCRSPLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2031Sponsor estimatePhase 1NCT06925542A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune DiseaseCRISPR Therapeutics · SLE (Systemic Lupus)RecruitingCRSPLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 30, 2029Sponsor estimatePhase 1/Phase 2NCT07804004A Safety and Efficacy Study Evaluating CTX112 in Subjects With Refractory Neurologic Autoimmune DiseaseCRISPR Therapeutics · Progressive Multiple Sclerosis (PMS)Not yet recruitingCRSPLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2033Sponsor estimatePhase 1/Phase 2NCT07549698Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune DiseaseCRISPR Therapeutics AG · Warm Autoimmune Hemolytic Anemia (WAIHA)RecruitingCRSPLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2038Sponsor estimateNo phase registeredNCT06208878A Long-term Follow-up Study of Subjects Who Received CRISPR CAR T Cellular TherapiesCRISPR Therapeutics AG · Hematologic MalignancyEnrolling by invitationCRSPLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2027Sponsor estimatePhase 1NCT07491172A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory DyslipidemiasCRISPR Therapeutics AG · CardiovascularRecruitingCRSPLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 8, 2025ActualPhase 1NCT05565248An Open-Label, FIH Study Evaluating the Safety, Tolerability, and Efficacy of VCTX211 Combination Product in Subjects With T1DCRISPR Therapeutics AG · Diabetes MellitusTerminatedCRSPLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2030Sponsor estimatePhase 1/Phase 2NCT05643742A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell MalignanciesCRISPR Therapeutics AG · B-cell LymphomaRecruitingCRSPLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 4, 2024ActualPhase 1/Phase 2NCT04035434A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)CRISPR Therapeutics AG · B-cell MalignancyTerminatedCRSPLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 30, 2024ActualPhase 1NCT04502446A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies (COBALT-LYM)CRISPR Therapeutics AG · T Cell LymphomaTerminatedCRSPLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 8, 2024ActualPhase 1NCT04438083A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory Renal Cell Carcinoma (COBALT-RCC)CRISPR Therapeutics AG · Renal Cell CarcinomaTerminatedCRSPLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 4, 2024ActualPhase 1NCT04244656A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple MyelomaCRISPR Therapeutics AG · Multiple MyelomaTerminatedCRSPLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 19, 2023ActualPhase 1NCT05210530An Open-Label, FIH Study Evaluating the Safety and Tolerability of VCTX210A Combination Product in Subjects With T1DCRISPR Therapeutics AG · Diabetes MellitusCompletedCRSPLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 7, 2025ActualPhase 2/Phase 3NCT03745287A Safety and Efficacy Study Evaluating CTX001 in Subjects With Severe Sickle Cell DiseaseVertex Pharmaceuticals Incorporated · Sickle Cell DiseaseCompletedVRTXLeadCRSPCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 30, 2039Sponsor estimatePhase 3NCT04208529A Long-term Follow-up Study in Participants Who Received CTX001Vertex Pharmaceuticals Incorporated · Beta-ThalassemiaEnrolling by invitationVRTXLeadCRSPCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 14, 2027Sponsor estimatePhase 3NCT05356195Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT)Vertex Pharmaceuticals Incorporated · Beta-ThalassemiaActive, not recruitingVRTXLeadCRSPCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 6, 2027Sponsor estimatePhase 3NCT05329649Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD)Vertex Pharmaceuticals Incorporated · Sickle Cell DiseaseActive, not recruitingVRTXLeadCRSPCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 13, 2025ActualPhase 2/Phase 3NCT03655678A Safety and Efficacy Study Evaluating CTX001 in Participants With Transfusion-Dependent β-ThalassemiaVertex Pharmaceuticals Incorporated · Beta-ThalassemiaCompletedVRTXLeadCRSPCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 21 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner